Despite the wide occurrence of crystallization in the pharmaceutical industry, deep understanding and fine control of the process remain a tricky issue. Nevertheless, the successful manufacturing of finished pharmaceutical products, as well as the structural determination of biopharmaceuticals, depend on the size, form, shape and purity of the crystals. The ability of substrates with precise chemistry and topological features to induce nucleation has been thoroughly assessed during the recent years. This paper reviews the major advances and discoveries in controlling small molecule drug and protein crystallization by means of engineered surfaces. By designing superficial properties and morphology, it has been possible to tune the polymorph outcome, shorten the nucleation induction time, impose specific crystal shapes, control the crystal size and carry out crystallization at very low supersaturation levels. Such achievements underline the potential of surface-induced crystallization to provide an ideal platform for the study of the nucleation process and gain control over its stochastic nature.

译文

:尽管在制药行业中发生了广泛的结晶,但是对过程的深入了解和精细控制仍然是一个棘手的问题。然而,成品药品的成功生产以及生物药品的结构确定取决于晶体的大小,形式,形状和纯度。近年来,已经对具有精确化学和拓扑特征的底物诱导成核的能力进行了全面评估。本文综述了通过工程表面控制小分子药物和蛋白质结晶的主要进展和发现。通过设计表面性质和形态,可以调节多晶型物的结果,缩短成核诱导时间,施加特定的晶体形状,控制晶体尺寸并以非常低的过饱和水平进行结晶。这些成就强调了表面诱导结晶的潜力,为研究成核过程和获得对其随机性的控制提供了理想的平台。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录